DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session

Learn about the latest in cannabidiol (CBD) early-stage drug development from Terry O’Regan, President Brains Bioceutical, and Alexandru Zabara, Innovation Manager Pharma at DSM.

Get an expert view on how to unlock cannabinoid therapeutic innovation by advancing the scientific landscape, as well as approaches to addressing the challenge of CBD bioavailability: modulating physical properties of selected formulations in order to enhance in-vitro bioaccessibility and in-vivo pharmacokinetic performance.

Request Free!

Comments are closed.